Clinical Trial Update: A PET/MRI Study of Cobenfy on Dopamine Transmission in Schizophrenia [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 PET/MRI study of Cobenfy assessing dopamine transmission in schizophrenia and schizoaffective disorder, currently not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizoaffective Disorder
• Schizophrenia

Drugs mentioned

• COBENFY (Xanomeline and Trospium Chloride)

Snippet

Sponsor: New York State Psychiatric Institute | Conditions: SCHIZOPHRENIA 1 (Disorder), Schizoaffecitve Disorder | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING